Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001052455 | SCV001216665 | uncertain significance | not provided | 2024-10-26 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 816 of the MYO7A protein (p.Arg816Cys). This variant is present in population databases (rs781926175, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with MYO7A-related conditions. ClinVar contains an entry for this variant (Variation ID: 848652). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt MYO7A protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV001578719 | SCV001806011 | uncertain significance | Autosomal dominant nonsyndromic hearing loss 11 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001578720 | SCV001806012 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 2 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001578721 | SCV001806013 | uncertain significance | Usher syndrome type 1 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001272503 | SCV001454575 | uncertain significance | Usher syndrome type 1B | 2020-09-16 | no assertion criteria provided | clinical testing |